Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of osimertinib versus placebo in resected EGFR-mutant stage IB-IIIA non-small cell lung cancer
CTR20160322Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of osimertinib in non-small cell lung cancer (NSCLC), sponsored by AstraZeneca. Started Oct 2016; status: completed.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20160322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20160322.